ClinicalTrials.gg
TerminatedNCT03521232Updated Nov 29, 2022

A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis

A Phase 1/2 interventional study of Niclosamide in Ulcerative Colitis, Ulcerative Proctitis and Ulcerative Proctosigmoiditis, sponsored by Entero Therapeutics. Terminated at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-29.

Sponsored by Entero Therapeutics · Phase 1/2, Interventional, and Other

Why this study was terminated
Covid-19

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 209 studies in Colitis, Ulcerative with a site in Italy — 48 open to participants now, 77 under way, 27 of them phase 3. Colitis, Ulcerative · Italy.

Enrollment
162nd of 175
27 · median 182
Started
2018
with 14 others
Phase 1/2
3 of 209
2 open now
Registered
82nd of 209
by date

Among the 209 studies in Colitis, Ulcerative with a site in Italy, this one is the 162nd largest by enrollment of the 175 interventional ones that give a count, is one of 15 that started in 2018, is one of 3 in phase 1/2, and was the 82nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

48 of the 209 studies in Colitis, Ulcerative with a site in Italy are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Colitis, Ulcerative with a site in Italy, or all of them as a file.
02

Study summary

This will be a phase I/IIa, open-label, three-stage, single center study aimed at investigating the safety, the efficacy (clinical and endoscopic effects) and the pharmacokinetics of Niclosamide enema 150 mg/60 ml and 450 mg/60 ml in subjects with mild-to-moderate UP and UPS, defined as a Modified Mayo Score (MMS) ≥ 4 and \< 8, with a stool frequency subscore (SFS) ≥ 1, a rectal bleeding sub-score (RBS) = 1 or 2, and an endoscopic subscore (mucosal appearance) = 1 or 2. At the endoscopic sub-score any degree of friability will be classified as having a sub-scale score of 2.

03

Conditions studied

  • Ulcerative Colitis
  • Ulcerative Proctitis
  • Ulcerative Proctosigmoiditis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged ≥ 18 years at the time of signing the ;
  2. Must understand and voluntarily sign an informed consent from (ICF) prior to any study-related assessments/procedures being conducted.
  3. Must be able to adhere to the study visit schedule and other protocol requirements;
  4. Diagnosis of UP or UPS with a duration of at least 3 months prior to the Screening Visit
  5. MMS score ≥4 to \< 8 (range: 0-9) prior to enrolment in the study.
  6. Availability to perform an endoscopy (colonoscopy or flexible rectosigmoidoscopy);

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis, or diverticular disease-associated colitis;
  2. UC extended more than 40 cm from the anal verge;
  3. Subjects who have had surgery as a treatment for UC or who, in the opinion of the Investigator, are likely to require surgery for UC during the study;
  4. History of any neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, psychiatric, endocrine, hematological disorder or disease or any other medical condition that, in the Investigator's opinion, would preclude participation in the study;
  5. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she was to participate in the study or confounds the ability to interpret data from the study;
  6. Pregnant or breast feeding females;
  7. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections (including but not limited to tuberculosis, atypical mycobacterial disease, and herpes zoster), (HIV), or any major episode of infection requiring hospitalization or treatment with intravenous (IV) or oral antibiotics within 4 weeks of screening;
  8. Subjects who have received any drug or device in the last 3 months;
  9. History of alcohol, drug, or chemical abuse within the last 6 months;
  10. Known to niclosamide or any in the formulation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    150 mg/60 ml

    Niclosamide enemas 150 mg/60 ml given twice daily for 6 weeks

    Drug: Niclosamide

  • Experimental
    450 mg/60 ml

    Niclosamide enemas 450 mg/60 ml given twice daily for 6 weeks

    Drug: Niclosamide

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of Niclosamide enemas 150 mg/60 ml and 450 mg/60 ml graded according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

    1. Number of subjects with serious adverse reactions (i.e. treatment-related) during 6 weeks of treatment with Niclosamide enemas; 2. Number of subjects with grade ≥ 3 adverse reactions during 6 weeks of treatment with Niclosamide enemas; 3. Number of subjects with grade ≥ 2 adverse reactions during 6 weeks of treatment with Niclosamide enemas.

    Time frame: baseline to 6 weeks

Secondary outcomes

  1. Number of subjects with clinical remission defined as MMS* ≤ 2 with no individual subscore >1 after 6 weeks of treatment

    Time frame: baseline to 6 weeks

Other outcomes

  1. Change in signs and symptoms (rectal bleeding and stool frequency) from baseline to 2, 4 and 6 weeks of treatment

    Time frame: from baseline to 2, 4 and 6 weeks

  2. Change in sigmoidoscopic score (mucosal appearance) from baseline to 6 weeks of treatment

    Time frame: baseline to 6 weeks

  3. Change in hs-CRP and fecal calprotectin from baseline to 2, 4 and 6 weeks of treatment

    Time frame: baseline to 2, 4 and 6 weeks

  4. Change in histology (Geboes index) from baseline to 6 weeks of treatment

    Time frame: baseline to 6 weeks

  5. Change in safety laboratory tests from baseline to 6 weeks of treatment

    the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided

    Time frame: baseline to 6 weeks

  6. Change in 12-lead ECG parameters from baseline to 2, 4 and 6 weeks of treatment

    1. PR interval 2. RR interval 3. QRS interval 4 QT interval 5. HR interval 6. QtcF interval. All intervals summarized descriptively by visit

    Time frame: baseline to 2, 4 and 6 weeks of treatment

  7. Change in heart rate from baseline to 2, 4 and 6 weeks of treatment

    summarized descriptively by visit and presented as shift tables

    Time frame: baseline to 2, 4 and 6 weeks

  8. Change in quality of life (12-item Short-Form) from baseline to 6 weeks of treatment

    Time frame: baseline to 6 weeks

  9. Plasma levels of niclosamide measured before and after dosing

    Time frame: baseline to 6 weeks

  10. Change in sitting systolic and diastolic blood pressure from baseline to 2, 4 and 6 weeks of treatment

    summarized descriptively by visit and presented as shift tables

    Time frame: baseline to 2, 4 and 6 weeks

  11. Change in body temperature from baseline to 2, 4 and 6 weeks of treatment

    summarized descriptively by visit and presented as shift tables

    Time frame: baseline to 2, 4 and 6 weeks

07

Study locations

1 site
  • Tor Vegata
    Rome, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Sep 2022, 52 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2018
First posted
May 11, 2018
StartActual
May 15, 2018
Primary completionActual
Sep 19, 2022
CompletionActual
Oct 4, 2022
Last update
Nov 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03521232
Lead sponsor
Entero Therapeutics
Responsible party
Sponsor
First posted
May 11, 2018
Start date
May 15, 2018
Primary completion
Sep 19, 2022
Completion
Oct 4, 2022
Last update
Nov 29, 2022

Study contacts

James Pennington, M.D.
study director · First Wave BioPharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niclosamide

Start the discussion